SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

INNV RSS Feed
Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, cash4, Peter Lynch, pharmacyman
Search This Board: 
Last Post: 7/22/2017 6:42:25 PM - Followers: 125 - Board type: Free - Posts Today: 0

  


http://www.innovuspharma.com

https://twitter.com/innovuspharma


http://shop.innovuspharma.com/
* shareholders, please consider purchasing product(s)


***ALERT***

Awaiting Official Announcement of FDA Approval for FlutiCare



 
FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.
 

 


The CEO has already signed an agreement for the manufacturing of FlutiCare

 
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.
 



 

Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)
 

 
 

Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.


Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.


Bassam Damaj, Ph.D.
President and Chief Executive Officer:


Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
 



Who are the major players at Innovus Pharma?




 

Share Structure:


Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 

 
 
Products:
https://www.ooyess.bargains/

http://www.innovuspharma.com/products_OTC_mh.php#top



Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call
http://finance.yahoo.com/news/innovus-pharma-ceo-provides-shareholder-101000536.html

https://www.youtube.com/watch?v=FT9MP0OiMqU

https://www.youtube.com/watch?v=w-FKfRaSj0Y

https://www.youtube.com/watch?v=f7YnqjVLVg0

https://www.youtube.com/watch?v=mqM_dY5Wz3s




Corporate Presentation November 2016 (8-K  11/1/2016)
http://client.irwebkit.com/innovuspharma/filings?qm_page=38298


Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)
http://finance.yahoo.com/news/upcoming-pdufa-anda-approval-dates-140000806.html


Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products
http://finance.yahoo.com/news/innovus-pharma-innv-targeting-3-150320014.html




Major 2016 Accomplishments:



 

 


Where can INNV products be seen?





 


Existing Product Lines @ Innovus Pharma:

http://shop.innovuspharma.com/


Newest Product:

http://www.prostagorx.com/

WHAT IS PROSTAGORX™?

PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


_________________________________________________________________________________________________________________________________________________________________________
















Are you looking to boost your brain health?r
               http://www.recalmax.com/


http://www.urivarx.com/





http://www.myandroferti.com/

https://www.myvesele.com/

https://www.ooyess.bargains/

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

INNV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:13:38 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:12:24 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:12:24 AM
INNV News: Current Report Filing (8-k) 06/20/2017 06:11:03 AM
INNV News: Current Report Filing (8-k) 06/19/2017 06:05:31 AM
PostSubject
#10696  Sticky Note $INNV Improving. We can handle it. Figure BooDog 07/21/17 05:45:08 AM
#9455  Sticky Note Heavily shorted almost 3 Mil shares looking to cover. cash4 05/23/17 10:41:56 AM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#10725   doesnt matter if it was good they would TrueTrades 07/22/17 06:42:25 PM
#10724   I assume we are expecting 2nd Q first jbdiver 07/22/17 01:51:09 PM
#10723   Q210Q will be a debacle. Needs to be twistedfreak 07/22/17 07:36:54 AM
#10722   Personally, I blame Honeycomb777 for the share price gi197845 07/21/17 11:14:04 PM
#10721   pick up under .13 and i will pm TrueTrades 07/21/17 07:51:19 PM
#10720   We certainly weren't wrong when you pumpers were ShawnP123 07/21/17 06:29:41 PM
#10719   innv .116 -4.13% on 203065 vol TrueTrades 07/21/17 05:33:31 PM
#10718   Wrong --- few months ago - you healthywelth 07/21/17 04:46:01 PM
#10717   Boo- I believe this stock is on it's ShawnP123 07/21/17 04:23:50 PM
#10716   Let's not put the cart before the horse ShawnP123 07/21/17 04:11:19 PM
#10715   HC 0.50 is a long way off if ShawnP123 07/21/17 04:09:39 PM
#10714   Applause for making ithers aware of a growing BooDog 07/21/17 03:46:01 PM
#10713   good luck, by the time fluticare is approved, TRUMPFORPRES 07/21/17 03:32:57 PM
#10712   The catalyst that will leve many in the BooDog 07/21/17 03:29:08 PM
#10711   You know you are diluting and you are TRUMPFORPRES 07/21/17 03:26:51 PM
#10710   Nayyyy, a non issue. We know they're diluting. BooDog 07/21/17 03:16:22 PM
#10709   190M o/s is a large number...I am hoping Honeycomb777 07/21/17 03:07:19 PM
#10708   I am very excited to hear that you Honeycomb777 07/21/17 03:01:00 PM
#10707   Honeycomb, I am a product "ambassador" of sorts, gi197845 07/21/17 02:11:16 PM
#10706   Mwilson1, all I can tell you is that gi197845 07/21/17 02:06:16 PM
#10705   Honeycomb777, next time you're out golfing with Dr.Damaj, gi197845 07/21/17 02:03:26 PM
#10704   We're in line to make much more than BooDog 07/21/17 01:03:57 PM
#10703   let me go SLOW for you... Honeycomb777 07/21/17 12:23:28 PM
#10702   500K shares.. dummy... that equates to $60k value TRUMPFORPRES 07/21/17 12:19:09 PM
#10701   Here's what I don't get...why is this guy Honeycomb777 07/21/17 12:15:30 PM
#10700   You're talking about A YEAR away imo. BooDog 07/21/17 10:17:24 AM
#10699   Boo- your comments are very naive. A significant ShawnP123 07/21/17 09:55:29 AM
#10698   ONCE AGAIN! STOP PROMOTING THIS SCAM! IT IS TRUMPFORPRES 07/21/17 09:53:31 AM
#10697   I'm totally in with my paltry 500K shares. Batermere 07/21/17 06:40:46 AM
#10696   $INNV Improving. We can handle it. Figure BooDog 07/21/17 05:45:08 AM
#10695   Several people are thinking o/s will be around Honeycomb777 07/20/17 08:47:50 PM
#10694   looks like medical device tricked a few indeed TrueTrades 07/20/17 07:50:11 PM
#10693   mwilson-Those could have been MM's covering short trades. ShawnP123 07/20/17 07:35:47 PM
#10692   INNV breakout potential. Eom BooDog 07/20/17 06:27:45 PM
#10691   Mwilson: put the BROKEN RECORD on IGNORE and Batermere 07/20/17 05:49:59 PM
#10690   Don't care who listens and who doesn't. I've twistedfreak 07/20/17 05:33:25 PM
#10689   That 82K was a sell at .121 twistedfreak 07/20/17 05:28:38 PM
#10688   I'm not one to get into reg sho BooDog 07/20/17 05:26:38 PM
#10687   260k shares of buying today but keep talking Mwilson1 07/20/17 05:26:37 PM
#10686   Dude go away, there was a 82k buy Mwilson1 07/20/17 05:24:15 PM
#10685   I'd love to know what you were looking twistedfreak 07/20/17 05:03:47 PM
#10684   Bullshit. Plain and simple. Today's volume was mostly twistedfreak 07/20/17 05:01:08 PM
#10682   Yup, you'd better cover NITE & CANT. BooDog 07/20/17 03:06:46 PM
#10681   Setting up for the breakout. About time. BooDog 07/20/17 02:28:01 PM
#10680   yep, go give each other a nice soothing twistedfreak 07/20/17 12:21:05 PM
#10679   oh God, you're one of them? Please. You twistedfreak 07/20/17 12:17:28 PM
#10678   Yeah good call, will do the same Mwilson1 07/20/17 11:03:53 AM
#10677   Who cares? I have them both on IGNORE. Batermere 07/20/17 11:02:30 AM
#10676   why would i have 2 accounts? I was TRUMPFORPRES 07/20/17 11:00:25 AM
#10675   Must be getting VERY close to fluticare approval. eom BooDog 07/20/17 10:44:29 AM
PostSubject